Advertisement

Combined BCMA and CD19 CAR T-Cells in Relapsed or Refractory Multiple Myeloma
Posted: 04/08/2022 | By: Matthew Stenger

Question 1 of 5

In a phase II trial, treatment with a combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 CAR T cells produced partial response or better in:

Choose 1

A
60% of patients
B
92% of patients
C
77% of patients
D
34% of patients

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage